FASEB J. Pierce now sold as Thermo Scientific
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by VASILE, E.
Right arrow Articles by DVORAK, H. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by VASILE, E.
Right arrow Articles by DVORAK, H. F.
(The FASEB Journal. 2001;15:458-466.)
© 2001 FASEB

Differential expression of thymosin ß-10 by early passage and senescent vascular endothelium is modulated by VPF/VEGF: evidence for senescent endothelial cells in vivo at sites of atherosclerosis

ELIZA VASILE1, YASUHIKO TOMITA, LAWRENCE F. BROWN, OLIVIER KOCHER and HAROLD F. DVORAK

Departments of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215, USA

1Correspondence: Beth Israel Deaconess Medical Center, Department of Pathology, RN 280 D, 330 Brookline Ave., Boston, MA 02215, USA. E-mail: evasile{at}caregroup.harvard.edu


   ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
 
VPF/VEGF acts selectively on the vascular endothelium to enhance permeability, induce cell migration and division, and delay replicative senescence. To understand the changes in gene expression during endothelial senescence, we investigated genes that were differentially expressed in early vs. late passage (senescent) human dermal endothelial cells (HDMEC) using cDNA array hybridization. Early passage HDMEC cultured with or without VPF/VEGF overexpressed 9 and underexpressed 6 genes in comparison with their senescent counterparts. Thymosin ß-10 expression was modulated by VPF/VEGF and was strikingly down-regulated in senescent EC. The ß-thymosins are actin G-sequestering peptides that regulate actin dynamics and are overexpressed in neoplastic transformation. We have also identified senescent EC in the human aorta at sites overlying atherosclerotic plaques. These EC expressed senescence-associated neutral ß-galactosidase and, in contrast to adventitial microvessel endothelium, exhibited weak staining for thymosin ß-10. ISH performed on human malignant tumors revealed strong thymosin ß-10 expression in tumor blood vessels. This is the first report that Tß-10 expression is significantly reduced in senescent EC, that VPF/VEGF modulates thymosin ß-10 expression, and that EC can become senescent in vivo. The reduced expression of thymosin ß-10 may contribute to the senescent phenotype by reducing EC plasticity and thus impairing their response to migratory stimuli.—Vasile, E., Tomita, Y., Brown, L. F., Kocher, O., Dvorak, H. F. Differential expression of thymosin ß-10 by early passage and senescent vascular endothelium is modulated by VPF/VEGF: evidence for senescent endothelial cells in vivo at sites of atherosclerosis.


Key Words: cDNA arrays • lipoproteins • human aorta


   INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
 
NONIMMORTALIZED MAMMALIAN CELLS have a finite life span in tissue culture. After a variable number of population doublings, mammalian cells begin to divide more slowly and eventually stop dividing altogether. This last state is referred as replicative senescence (1 , 2) . Senescence is not to be confused with cell death in that senescent cells can survive and remain metabolically active for long periods (3) . Replicative senescence can be delayed and, in some instances, reversed by genetic modifications such as transfection with SV40 large T antigen (4 , 5) , activation of the telomerase gene (6 , 7) , inactivation of p53 (8) , or by culture with various cytokines (12 13 14) . It has also been possible to identify senescent human cells in vivo based on their morphology and expression of neutral ß galactosidase (9 , 10) .

In recent years, senescence has become an increasingly important topic of scientific investigation because of its relevance to such age-related diseases as atherosclerosis, Alzheimer’s disease, diabetes and the more general problem of organismic aging. While generally regarded as disadvantageous to the host, senescence may in some instances be of benefit as, for example, in limiting the division of premalignant cells and therefore delaying tumorigenesis. Also, anticancer agents have been reported to induce a senescence-like phenotype that may provide an important evaluation tool for assessing treatment efficacy (9 10 11) .

Like other mammalian cells, endothelial cells (EC) have a finite proliferative life span in culture. After ~20–25 population doublings, a substantial fraction of cells become enlarged and are often multinucleated with a veil-like cytoplasm that is intensely positive for senescence-associated neutral ß-galactosidase (SA ß-Gal). Such EC may survive in a nonproliferative mode for at least several months (10 , 12) . Moreover, the onset of EC senescence can be delayed or prevented by certain growth factors, including VPF/VEGF, TGF-ß, IGF, or IL-1{alpha} (12 13 14) .

Although it is certain that endothelial cells undergo replicative senescence in culture, it has not been shown that they do so in vivo. The EC lining both large and small vessels of normal adults are quiescent cells that seldom divide and turn over very slowly (15 , 16) . Little is known about the capacity of large vessel (e.g., aorta) endothelium to replicate in vivo. However, microvascular EC are not to be regarded as senescent because they retain the capacity to divide rapidly in response to cytokines and growth factors emitted by tumors, wounding, inflammation, etc. (17 18 19) . Nonetheless, there have been suggestions of slowed microvascular EC replication in vivo with aging. Thus, the angiogenic response to tumors and ischemia is impaired in older animals and can be corrected, at least in part, by administration of VPF/VEGF (20 21 22) . This last finding is of particular interest because of VPF/VEGF’s ability to regulate EC gene expression and delay EC senescence in vitro.

The goal of this study was twofold: 1) to investigate altered gene expression in senescent vascular endothelium and 2) to determine whether vascular endothelium undergoes senescence in vivo. We report here that early passage human dermal endothelial cells (HDMEC) cultured with or without VPF/VEGF overexpressed 9 genes and underexpressed 6 others in comparison with their senescent counterparts. Of particular interest was the finding that VPF/VEGF regulates thymosin ß-10 expression and that thymosin ß-10 was strikingly down-regulated in senescent EC. The ß-thymosins are a large family of monomeric actin-sequestering peptides that regulate cell proliferation (23) and actin dynamics, important processes in cell migration, angiogenesis, neurogenesis, etc. (24 , 25) . With regard to the second goal, we found that EC overlying atherosclerotic lesions in the aorta were strongly SA ß-Gal-positive but reacted only weakly with antibody to thymosin ß-10, i.e., they exhibited the senescence phenotype.


   MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
 
Reagents
Dulbecco’s minimal essential medium, fetal calf serum, and calf serum were purchased from JRH Laboratories (Lenexa, Kans.), endothelial basal medium (EBM), medium without serum, and endothelial growth medium (EGM, medium containing 2 to 10% fetal bovine serum) were from Clonetics (San Diego, Calif.); collagen type I was from Collagen Biomaterials (Palo Alto, Calif.); recombinant human vascular endothelial growth factor (rVEGF) and recombinant human tumor necrosis factor alpha (rTNF-{alpha}) were from R&D Systems (Minneapolis, Minn.). All other tissue culture reagents were purchased from Gibco-BRL. 3,3'Diaminobenzidine tetrachloride (DAB) developing color reagent was purchased from Zymed Laboratories (San Francisco, Calif.). SuperSignal Chemiluminescent System was from Pierce (Richmond, Ill.); biotinylated Ulex Europaeus agglutinin-1 and Vectashield were from Vector Laboratories (Burlingame, Calif.). Other reagents were from Sigma (St. Louis, Mo.).

Antibodies
Rabbit anti thymosin ß-10 antibody (serum) No.1 was a generous gift of Dr. Helen Yin (University of Texas Southwestern Medical School, Dallas, Tex.). To generate anti-thymosin ß-10 No.2 antibody, the carboxyl-terminal thymosin ß-10 specific peptide TIEQEKRSEIS was synthesized, coupled to keyhole limpet hemocyanine (KLH) (Genemed Synthesis Inc, San Francisco, Calif.) and injected into New Zealand White rabbits (Lampire Biological Laboratories, Pipersville, Pa.). The rabbit preimmune and immune IgG were purified by protein A Sepharose chromatography. Other antibodies used in this study were mouse anti-human endothelial leukocyte adhesion molecule-1 (ELAM-1/CD62E), mouse monoclonal anti-human platelet endothelial cell adhesion molecule (PECAM/CD31) from R&D Systems; rabbit anti-human CD31, a generous gift from Dr. H. M. Delisser (University of Pennsylvania, Medical Center, Philadelphia), Dynabeads M-450-coated with goat anti-mouse IgG from Dynal (Lake Success, N.Y.). Fluorescein isothiocyanate (FITC) and Texas red conjugated secondary antibodies were obtained from Cappel Organon Teknika (Durham, N.C.), donkey anti-rabbit IgG coupled to Cy5 was purchased from Jackson Immunoresearch Laboratories (West Grove, Pa.); biotinylated goat anti-rabbit IgG, biotinylated goat anti-mouse IgG (Vectastain ABC kits) were from Vector Laboratories.

Endothelial cell Isolation and culture
Human dermal microvascular endothelial cells (HDMEC) were isolated from human neonatal foreskins (26) . Three to five foreskins were pooled, finely minced, and digested with collagenase type XI (5 mg/ml, Sigma) for 60 min at 37°C. The tissue digest was filtered through a 70 µm nylon filter (Falcon) and the filtrate centrifuged at 1000 g. Pelleted cells and cell clusters were further dissociated with trypsin (0.05%, 15 min at 37°C), incubated with 10% serum-containing media, and recentrifuged. Cells were then plated on collagen I (50 µg/ml) -coated plates in EGM containing 10% fetal bovine serum, 25 ng/ml cyclic adenosine monophosphate, 1 µg/ml hydrocortisone and antibiotics. Two to three days later, EC were selectively activated with TNF-{alpha} (100 ng/ml, 4 h) and recovered apart from contaminating cells with ELAM-1-coated dynabeads. This step was repeated twice in order to completely eliminate nonendothelial cell contaminants. HDMEC purity was judged by morphology, expression of CD31 antigen and by the uptake of DiI-acetylated LDL (DiI-Ac-LDL). Endothelial cells were maintained in tissue culture with or without 50 ng/ml VEGF. The cells were serially propagated in tissue culture in such a manner that, with each passage, cells increased by two population doublings (PD). HDMEC cultured without VPF/VEGF became replicative senescent after PD 24–26.

Low density lipoproteins
Low density lipoproteins (LDL) were separated from human plasma as described previously (27 , 28) . LDL were extensively dialyzed against 0.15 M NaCl solution containing 1 mM EDTA, 1 mM butylated hydroxy-toluene (BHT). Protein content was measured by a modified Lowry assay (29) . LDL was then fluorescently labeled with 1,1'-dioctadecyl 3,3' tetramethyl indocarbocyanine perchlorate (DiI-LDL) as described (30) . DiI-oxidized LDL (DiI-ox-LDL) was prepared by dialysis against 0.1 M NaCl solution, pH 7.4, containing 5 µM CuSO4 for 16 h at 4°C. Oxidation was terminated by dialysis against 0.1 M NaCl, pH 7.4, supplemented with 5 mM EDTA and 0.1 mM BHT. DiI-acetylated-LDL (DiI-Ac-LDL) was prepared as described previously (31) or was purchased from Biomedical Technologies Inc. (Stoughton, Mass.). LDL was radio-iodinated by the ICl method as modified by Bilheimer et al., (32) . Specific activity ranged from 120 to 250 cpm/ng LDL protein.

125I-oxLDL uptake and degradation assays
HDMEC (PD12 and PD26) were plated at 250 K cells per well in 6-well dishes and maintained in EGM for 48 h, after which cells were incubated in EBM containing 3% (v/v) newborn calf lipoprotein-deficient serum for 16 h. Thereafter, the cells were rinsed with fresh serum-free medium and cultured for 5 h at 37°C with fresh medium supplemented with 10 µg/ml 125I-oxLDL in the absence (duplicate determinations) or presence of 400 µg/ml unlabeled ox-LDL (single determinations). Culture supernatants were recovered and 125I-oxLDL degradation products released by the cells into the media were measured as described previously (31 , 33) . In brief, culture supernatants were precipitated with 20% trichloro-acetic acid (TCA); TCA supernatants were treated with potassium iodide and H2O2 and then extracted with chloroform to remove free iodine. Aliquots of the aqueous phase of the chloroform extracted supernatants were subjected to gamma counting to provide a measure of degraded ox-LDL expressed as nanograms of 125I-ox-LDL degraded per milligram of cell protein in 5 h. Cell monolayers were rinsed with cold phosphate-buffered saline (PBS) and dissolved in 0.1 N NaOH. Aliquots of cell extracts were used to measure cell protein and the remainder was subjected to gamma counting to measure cell uptake of 125I-oxLDL.

Senescence associated ß-galactosidase (SA ß-Gal) staining
Cultured cells were rinsed in PBS, fixed in 4% formaldehyde in PBS for 4 min at room temperature, then briefly washed in PBS and incubated with ß Gal solution (pH 6.0) for 8–16 h at 37°C (10) .

Human aorta and skin samples
Portions of human aortic arch exhibiting atherosclerotic lesions were collected from three patients, all older than 70 years, at autopsy (18–24 h postmortem) and fixed in 4% formaldehyde in PBS for 1 h. Segments of aorta were subjected to SA ß-Gal staining directly as above. Portions of blue staining and adjacent nonstaining (normal) aortic arch were snap-frozen in Tissue Tek O.C.T. embedding medium (Ted Pela, Reading, Calif.).

Immunohistochemistry
Frozen sections (10 µm thick) of blue staining and normal-appearing aortic arch were incubated in PBS containing 0.3% hydrogen peroxide for 30 min to quench tissue endogenous peroxidases, rinsed in PBS, and then incubated with 50 mM sodium borohydride for 30 min to quench the nonspecific binding and autofluorescence of elastin. To block nonspecific binding and to permeabilize the tissue, the sections were further incubated in PBS containing 1% bovine serum albumin (BSA) and 0.1% saponin at 4°C, overnight. Sequential tissue sections were then incubated with mouse monoclonal anti-human CD31 (10 µg/ml) or rabbit anti-human thymosin IgG (1 µg/ml) (No.2 antibody). As negative controls, normal mouse IgG, normal rabbit IgG, preimmune rabbit IgG (serum collected before immunizing the rabbits with thymosin ß-10) were used instead of the first antibody at the same protein concentration as the corresponding primary antibodies or the first antibody was omitted. Secondary antibodies (goat anti-mouse or goat anti-rabbit biotinylated IgG, respectively) were then applied followed by avidin-peroxidase according to the manufacturer’s protocol (Vector). The peroxidase reaction was developed using DAB plus kit for 5 min. CD-31 antigen detection on aortic endothelial layer was further amplified by using DAB enhancer according to the manufacturer protocol (Zymed Laboratories). Other sections were reacted with biotinylated Ulex Europaeus agglutinin-1 and developed with avidin-peroxidase and AEC substrate (Zymed Laboratories). The slides were washed, dehydrated and mounted with Cytoseal mounting medium (Fisher Scientific, Pittsburgh, Pa.), viewed and photographed with a Zeiss Axiophot microscope system and Kodak Ektachrome film.

Immunofluorescence
PD 12 and PD 26 HDMEC grown on collagen-coated coverslips were fixed with 4% formaldehyde in PBS for 1 h at room temperature. Cells were then incubated for 30 min with PBS containing 1% BSA to block nonspecific binding and were permeabilized in PBS - 0.1% saponin - 1% BSA for 30 min. Cells were then incubated with rabbit anti-thymosin ß-10 antibody (1: 200 serum No.1 or 1 µg/ml IgG obtained from serum No.2), washed in PBS, and incubated with 1: 500 goat anti-rabbit FITC-IgG (secondary antibody). After further washing with PBS, the cells were mounted on microscope slides with Vectashield (Vector). A similar procedure was used for aortic frozen fixed sections (see Immunohistochemistry above). As negative controls, normal rabbit IgG and preimmune serum were used instead of the first antibody or the first antibody was omitted (34) .). For aortic sections, to avoid any elastin blue autofluorescence the secondary antibody was donkey anti-rabbit IgG coupled to Cy5 (far-red fluorescence fluorophore). Cell nuclei were stained with propidium iodide. The samples were viewed with a Bio-Rad MRC-1024 confocal microscope. For photographic reproduction, the Cy5 far-red fluorescence was converted to a green display with Bio-Rad Lasersharp RGB merge software.

Differential gene expression
Poly A+ RNAs were isolated from PD 12 and PD 26 HDMEC cultured with or without VPF/VEGF from the time of isolation using a commercial kit (Clontech, Palo Alto, Calif.). 32P-labeled ATP-cDNA probes were generated by reverse transcription of purified poly(A)+ RNAs. cDNA probes prepared from PD12 and PD 26 HDMEC were hybridized in parallel on identical cDNA array membranes (Human Atlas Array I, Clontech Laboratories Inc., Palo Alto, Calif.) according to the manufacturer’s instructions (Clontech # PT3140–1). Each membrane contained 588 human cDNAs spotted in duplicate. Plasmid and bacteriophage DNAs were included as negative controls to confirm hybridization specificity along with nine housekeeping cDNAs as positive controls for normalizing mRNA abundance. The spotted cDNAs were arrayed into six functional classes: oncogenes, stress response, apoptosis, transcription factors, receptors, and cytoskeleton motility genes. The hybridized membranes were exposed to BioMax MS film (with a BioMax TranScreen intensifying screen), (Eastman Kodak, New Haven, Conn.) at -70°C for 5–7 days.

Northern blotting
Total RNA and mRNA were extracted from PD 12 and PD 26 HDMEC cultured with or without VPF/VEGF using a Qiagen kit according to manufacturer’s protocol (Qiagen, Valencia, Calif.). Northern blots were hybridized with a 32P-labeled CTP thymosin-ß 10 probe that was generated by RT-PCR from a human uterus cDNA library using oligonucleotide primers (Clontech, Palo Alto, Calif.). A probe specific for the ribosome associated protein 36B4 was used to control for RNA loading. Hybridized blots were exposed to BioMax MS film that was scanned at 100 µm pixel size using a Molecular Dynamics densitometer (Sunnyvale, Calif.). Digitized images were analyzed by ImageQuant software (Molecular Dynamics) using ‘the local background’ correction method.

In situ hybridization
Human thymosin-ß 10 cDNA (300 bp, spanning from 40 to 340 bp of 400 bp entire coding region) was subcloned into a pGEM-1 vector (Promega, Madison, Wis.) from which single-stranded (sense and antisense) RNA probes were synthesized (108 cpm/µg) with 35S-UTP, purified on polyacrylamide gels, and used without reduction in length. In situ hybridization was performed as described previously (35) .


   RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
 
Analysis of differentially expressed genes
As previously reported (12) , VPF/VEGF delayed the onset of senescence in HDMEC. HDMEC cultured without VPF/VEGF exhibited growth arrest or replicative senescence by PD 24–26 whereas HDMEC cultured continuously with VPF/VEGF continued to proliferate beyond PD 38–40. To investigate the underlying mechanisms, we made use of cDNA expression arrays to compare the genes expressed by early passage PD12-HDMEC cultured with VPF/VEGF with those expressed by growth-arrested, senescent PD 26 HDMEC cultured without VPF/VEGF. Autoradiographic analysis of paired cDNA expression arrays revealed that 9 genes were relatively overexpressed by PD 12 HDMEC cultured with VPF/VEGF whereas 6 different genes were relatively overexpressed by senescent PD 26 HDMEC (Fig. 1 ). Genes relatively overexpressed by PD 12 HDMEC included Tie-1, thrombin receptor, integrin {alpha}-5, {alpha}-catenin, endothelin, HSP 27, monocyte chemotactic and activating factor (MCAF), ICAM-1, and thymosin ß-10 genes. Significantly overexpressed by senescent PD 26 HDMEC were growth arrest and DNA damage-inducible protein (GADD) 153, integrin ß 1, PDGF receptor-{alpha}, basic fibroblast growth factor (bFGF) receptor, DNA binding protein TAXREB67, and nuclease sensitive DNA binding protein genes. Both of the high-affinity VPF/VEGF receptors, VEGFR-1 (flt-1) and VEGFR-2 (KDR), were expressed equally and at low levels by both PD 12 and PD 26 HDMEC. Thymosin ß-10 was the most up-regulated gene in early passage as compared to senescent/late passage HDMEC. Gene expression in PD12 HDMEC cultured with or without VPF/VEGF was similar except that Tie-1 was expressed relatively less in cells cultured without VPF/VEGF. HDMEC cultured continuously with VPF/VEGF through PD 26 did not exhibit the senescence phenotype.



View larger version (65K):
[in this window]
[in a new window]
 
Figure 1. Autoradiographs of paired identical human cDNA expression blots (Atlas, Clontech) hybridized with mRNA from A) early passage PD-12 HDMEC cultured with VPF/VEGF and B) late passage, senescent PD-26 HDMEC cultured without VPF/VEGF. The arrays contained immobilized cDNA probes for growth factors, cytokines, interleukins, and extracellular cell signaling proteins. 4d represents thymosin ß-10 and 3g bFGF receptor.

Relative overexpression of thymosin ß-10 transcript by PD 12 HDMEC was confirmed by Northern blotting (Fig. 2A ) and was found to be three- to fourfold more abundant in PD 12 HDMEC (cultured with or without VPF/VEGF) than in senescent PD 26 cells (Fig. 2B ). As expected from analysis of cDNA expression arrays, addition of exogenous VPF/VEGF to culture medium induced only a small additional increase in the expression of thymosin ß-10 in early passage (PD 12) HDMEC (Fig. 2) ; however, HDMEC cultured continuously with VPF/VEGF from initial seeding through PD 26 expressed ~ twofold more thymosin ß-10 than PD 26 HDMEC cultured without VPF/VEGF (Fig. 2B , compare lane 3 and 4).



View larger version (30K):
[in this window]
[in a new window]
 
Figure 2. A) Northern blot analysis of thymosin ß-10 mRNA expression in early passage PD-12 and late passage, senescent PD-26 HDMEC. Cells had been cultured with (+) or without (-) VPF/VEGF from the time of initial seeding. A cDNA probe to the ribosome-associated protein 36B4 was used as a control for RNA loading. B) Relative abundance of thymosin ß-10 mRNA as determined by densitometric analysis of the Northern blot in panel A after correction for RNA loading.

Cellular distribution of thymosin ß-10 protein
The distribution of thymosin ß-10 was compared in early passage PD12 HDMEC and in senescent PD26 HDMEC by confocal fluorescence microscopy. PD 12 HDMEC, cultured with or without VPF/VEGF, exhibited intense, diffuse cytoplasmic staining for thymosin ß-10 (Fig. 3A , B ). Staining was considerably weaker in PD 26 HDMEC cultured without VPF/VEGF and exhibiting the senescence phenotype (enlarged, multinucleated, with veil-like cytoplasm) (Fig. 3C ). PD 26 HDMEC grown with VPF/VEGF did not become senescent and their thymosin ß-10 staining was similar to that of PD 12 HDMEC (data not shown).



View larger version (51K):
[in this window]
[in a new window]
 
Figure 3. Confocal immunofluorescence visualization of thymosin ß-10 in early passage PD-12 and senescent PD-26 HDMEC. Cells had been cultured with (A) or without VPF/VEGF (B, C) from the time of isolation. PD-12 HDMEC cultured with or without VPF/VEGF exhibit strong cytoplasmic staining for thymosin ß-10 (A, B) whereas staining is much weaker in enlarged senescent PD-26 HMDVEC (C). Senescent HDMEC have a characteristic morphology (greatly enlarged, sometimes multinucleate cells with veil-like cytoplasm). Magnification bars: 20 µm.

Immunohistochemical detection of senescent cells in human aorta
To determine whether senescent endothelial cells were present in situ, segments of human aorta obtained at autopsy from elderly patients were processed for SA ß-Gal staining. Zones (1–4 mm in diameter) of characteristic blue luminal staining developed over atherosclerotic plaques on the aortic arch and adjacent to the carotid bifurcation (Fig. 4A , B ). This finding was confirmed by histochemistry as a thin, continuous layer of luminal SA ß-Gal staining; scattered cells located immediately beneath the endothelial layer (possibly representing macrophages or smooth muscle cell) also stained (Fig. 4C ).



View larger version (45K):
[in this window]
[in a new window]
 
Figure 4. Aortic arch tissue taken at autopsy. A) Luminal surface demonstrates patchy blue SA ß-Gal staining over atherosclerotic plaques. B) Hematoxylin-eosin stained frozen section taken through an area of surface bluing illustrates underlying atherosclerotic plaque. C) Section through SA ß-Gal-positive region of aortic arch illustrates blue staining that is confined to the luminal surface and focally to cells immediately beneath the surface, macrophages, or smooth muscle cells. Magnification bars: A), 2 mm; B), 500 µm; C), 20 µm.

Next we compared the distribution of thymosin ß-10 in SA-ß-Gal-positive and -negative regions of aortic arch (Fig. 5 ). The SA ß-Gal-positive endothelial layer overlying atherosclerotic lesion stained less intensely for thymosin ß-10 than adjacent ß-Gal-negative endothelium (Fig. 5A , B ). Immunostaining with CD31 confirmed that the SA-ß-Gal-positive area of staining of the aortic lumen in fact represented endothelium (Fig. 5C ); a similar thin layer of CD31 immunostaining was also observed in SA-ß-Gal-negative portions of the aorta. Endothelial cells lining small adventitial vessels in the aortic adventitia stained strongly for thymosin ß-10 (Fig. 5D ). Taken together, these results demonstrate that EC overlying atherosclerotic plaques exhibit characteristics of senescence (strong staining for SA-ß-Gal and weak staining for thymosin ß-10).



View larger version (81K):
[in this window]
[in a new window]
 
Figure 5. Immunoperoxidase staining for thymosin ß-10 in sections taken through SA ß-Gal-positive and normal-appearing regions of human aorta. Note relatively weak thymosin ß-10 staining of the luminal endothelial lining the SA ß-Gal-positive region (A) compared with the relatively stronger staining of the adjacent normal aortic endothelium (B). Macrophage-like cells, in subendothelial area, of both SA-ß-Gal-positive and -negative zones also stained strongly for thymosin ß-10 (A, B, arrows). The luminal layer that was SA ß-Gal-positive also stained positively for the CD31 antigen, indicating it represented endothelium (C). Microvessels associated in the adventitia of the same aortic section were strongly reactive for thymosin ß-10 protein (D). Magnification bars: 100 µm.

Uptake of modified lipoproteins by HDMEC
Oxidized LDL are thought to play an important role in atherosclerosis and may contribute to arterial wall inflammation and cellular injury (36) . Both ox-LDL and ac-LDL bind to a set of functionally overlapping receptors expressed on vascular endothelium. They are subsequently internalized by receptor-mediated endocytosis and are then degraded in lysosomes (36 , 37) . At PD 20, up to 10% of the HDMEC population cultured without VPF/VEGF exhibited the characteristic cell enlargement and SA-ß-Gal positivity of senescence. When PD 20 cells were incubated with DiI-ox-LDL or DiI-ac-LDL (10 µg/ml) for 5 h at 37°C, cells exhibiting the senescence phenotype exhibited more extensive uptake of both tracers than smaller, normal-sized nonsenescent endothelial cells (Fig. 6A , B ).



View larger version (42K):
[in this window]
[in a new window]
 
Figure 6. PD-20 HDMEC cultured without VPF/VEGF were incubated with DiI-ac-LDL and then processed for SA ß-Gal staining. A) Two enlarged senescent HDMEC strongly express SA ß-Gal. B) Fluorescence microscopy of the same field illustrates abundant uptake of DiI-ac-LDL by the two enlarged SA ß-Gal-positive cells (arrows) illustrated in panel A. Magnification bars: 20 µm.

To quantitate lipoprotein uptake and degradation by early passage and senescent HDMEC, we incubated PD12 and senescent PD 26 HDMEC (both cultured without VPF/VEGF) with 125I-ox-LDL. After 5 h at 37°C, similar amounts of 125I ox-LDL per milligram cell protein were found in PD 12 and PD 26 HDMEC. In a typical experiment (one of three), early passage PD 12 HDMEC contained 563 ± 39.5 ng 125I ox-LDL/mg cell protein vs. 548 ± 42.5 ng 125I ox-LDL/mg cell protein in senescent PD26 HDMEC. However, lipoprotein degradation was more than threefold greater in PD12 HDMEC than in PD 26 HDMEC: 446 ± 2.2 ng protein I125 ox-LDL/mg cell protein/5 h in culture medium of PD 12 vs. 130 ± 11.5 ng protein 125I ox-LDL/mg cell protein/5 h in culture medium of PD26 HDMEC. These results demonstrate that although individual enlarged senescent HDMEC stored larger amounts of lipoproteins than individual early passage cells, the content of lipoprotein did not differ in senescent and early passage HDMEC when expressed as lipoprotein per milligram cell protein. Furthermore, the data indicate that atherogenic oxidized lipoprotein degradation is greatly reduced in senescent endothelium.

Detection of thymosin ß-10 in human adenocarcinomas of the colon and in the tumor microvasculature
Thymosin ß-10 is expressed in many tissues and in increased amounts in certain tumors including melanomas and carcinomas of the kidney, ovary, and medullary carcinoma of the breast (23 , 38) . We have now extended this finding to another important human tumor, demonstrating that adenocarcinomas of the colon express much more thymosin ß-10 than adjacent normal epithelium (Fig. 7A , B ). Given the strong expression of thymosin ß-10 in actively dividing, early passage microvascular endothelium, we hypothesized that thymosin ß-10 might also be strongly expressed in tumor blood vessels. In fact, high levels of thymosin ß-10 mRNA were found by in situ hybridization in endothelial cells lining tumor microvessels (Fig. 7E ); however, thymosin ß-10 mRNA was also expressed strongly by vascular endothelium in adjacent, nonneoplastic tissue sections (Fig. 7E ). Similar results were obtained by immunohistochemical staining with an antibody to thymosin ß-10.



View larger version (132K):
[in this window]
[in a new window]
 
Figure 7. In situ hybridization illustrates thymosin ß-10 mRNA expression and distribution in human colon cancer and adjacent normal colon. A, C, E) Hybridizations performed with antisense probes to thymosin ß-10 mRNA; B, D, F) hybridizations performed with a control sense probe (A, C). Intense expression of thymosin ß-10 mRNA in tumor (T) as compared with adjacent normal (N) epithelium as observed by dark-field (A) or bright-field (C) microscopy. Neither tumor cells nor normal epithelium hybridized with the control sense probe (B, D). Endothelial cells lining tumor-supplying microvessels (V) hybridized strongly with the antisense probe (E) but not with the sense probe (F). Bars: 200 µm.


   DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
 
This study reports several novel findings. First, we demonstrated for the first time that thymosin ß-10 is differentially expressed in early passage HDMEC as compared with late passage, senescent HDMEC that result from prolonged culture without exogenous VPF/VEGF. Among the 588 genes evaluated by differential array hybridization, thymosin ß-10 was the gene most down-regulated in senescence. This finding was confirmed by Northern blotting and immunostaining. Supplementation of medium with VPF/VEGF from the time cultures were initiated significantly delayed loss of thymosin ß-10 expression as well as other properties of the senescence phenotype, including cell enlargement and SA ß-Gal staining (12) . The fact that early passage HDMEC expressed large and equivalent amounts of thymosin ß-10 in the presence or absence of exogenous VPF/VEGF suggests that VPF/VEGF is not necessary for maintaining thymosin ß-10 expression in the short term. Very likely, early passages EC already express maximal levels of thymosin ß-10. However, VPF/VEGF did increase thymosin ß-10 expression in late passage presenescent HDMEC, which expressed much lower levels of thymosin ß-10 than early passage cells.

Thymosin ß-10 is an actin G-sequestering protein that is highly expressed in embryonic and tumor cells (23 , 38 , 49 , 50) , a finding we have extended here to adenocarcinomas of the colon. It is thought to regulate the dynamics of the actin cytoskeleton and thereby modulate cell motility (51 , 52) and its overexpression is reported to accelerate apoptosis (53) . The great majority of malignant tumors overexpress both VPF/VEGF and thymosin ß-10 and have a proclivity for apoptosis. The mechanisms by which added VPF/VEGF maintains thymosin ß-10 expression and delays senescence in cultured HDMEC are not well understood and require further investigation.

A second novel finding was that the aortic endothelium overlying atherosclerotic plaques exhibited properties of senescence, i.e., were SA ß-Gal-positive and stained only weakly for thymosin ß-10. In contrast, the endothelium covering nearby regions of relatively normal aorta were SA ß-Gal-negative and stained strongly for thymosin ß-10. These observations are consistent with earlier work performed on the aortic endothelium of hyperlipidemic rabbits that demonstrated that endothelial cells overlying developing atherosclerotic plaques were greatly enlarged and lipid filled, thus presenting a phenotype consistent with the senescence reported here (41 , 42) . Similarly, enlarged multinucleated EC have been reported overlying advanced plaques in human atherosclerosis (43) . Other investigators have reported that cultured endothelial cells treated with oxidized LDL exhibited some morphological characteristics (blebbing and marked loss of viability) similar to those of EC covering atherosclerotic areas (44) . Together, these data provide strong evidence that endothelial cells overlying atherosclerotic plaques undergo senescence and therefore the large vessel vascular endothelium has the capacity to undergo senescence in vivo as well as in vitro.

A third finding concerned differences in turnover of DiI-ac-LDL and DiI-ox-LDL by senescent and nonsenescent endothelium. Both early passage and senescent HDMEC endocytosed large amounts of DiI-ac LDL and DiI-ox-LDL after 5 h of incubation. Individual large, senescent HDMEC contained substantially more fluorescent lipoprotein than their smaller, nonsenescent counterparts. This finding likely reflects the larger lysosomal compartment that has been described in senescent endothelial cells (39 , 40) . However, when considered in terms of lipoprotein incorporated per milligram EC protein, no difference was found in the amounts of lipoprotein incorporated by senescent or nonsenescent HDMEC. We did, however, find that early passage EC degraded almost threefold more lipoprotein than senescent cells over the same period of time, indicating a substantial reduction in the capacity of senescent EC to metabolize atherogenic lipids. Oxidized LDL are known to stimulate EC proliferation, and perhaps thereby the aging process (45 , 46) and directly up-regulate the expression of stress-related proteins, such as heat shock protein 70 (HSP 70) in human umbilical vein endothelial cells (HUVEC) (47) . We found that one stress-related protein, HSP 27, was slightly up-regulated in actively dividing early passage HMDEC grown in the presence of the VPF/VEGF as compared with senescent cells.

Senescence-associated gene expression was also measured recently in HUVEC by microarray analysis (48) . Of the 12 genes that were up-regulated in early passage HUVEC, only four (cyclins A and B1, cdc2, and HSP 70B) were represented in our array, and we found that none of these was up-regulated in early passage vs. senescent HDMEC. However, we did find that another heat shock protein, HSP 27, was up-regulated in PD 12 HDMEC. Of the 17 genes that Shelton et al. (48) found up-regulated in senescent HUVEC, only 4 were represented in our array: one of these, GADD 153, was also relatively overexpressed in senescent HDMEC; levels of two (adenosine A2A receptor and TGF-ß 2) were unchanged; and one (ICAM-1) was actually down-regulated in senescent as compared with early passage HUVEC. These data indicate that even in cells of the same general type (vascular endothelium), large differences in gene expression are to be expected when cells are isolated from different vascular beds (in this case, HDMEC vs. HUVEC) and that environmental factors (e.g., culture conditions) may significantly affect gene expression in addition to passage doubling number. These findings emphasize the importance of demonstrating differences in gene expression in vivo (here for thymosin ß-10) as well as in vitro.


   ACKNOWLEDGMENTS
 
We thank Eleanor J. Manseau and Kathy Tognazzi for technical assistance. This work was supported by the United States Public Health Service National Institutes of Health grants CA-50453 and HL-54465 (to H.F.D.).

Received for publication February 1, 2000. Revision received May 15, 2000.
   REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
 

  1. Campisi, J., Dimri, G. P., Nehlin, J. O., Testori, A., Yoshimoto, K. (1996) Coming of age in culture. Exp. Gerontol. 31,7-12[Medline]
  2. Smith, J. R., Pereira-Smith, O. M. (1996) Replicative senescence: implications for in vivo aging and tumor suppression. Science 273,63-67[Abstract]
  3. Wang, E. (1995) Senescent human fibroblasts resist programmed cell death, and failure to suppress bcl2 is involved. Cancer Res 55,2284-2292[Abstract/Free Full Text]
  4. Ades, E. W., Candal, F. J., Swerlick, R. A., George, V. G., Summers, S., Bosse, D. C., Lawley, T. J. (1992) HMEC-1: establishment of an immortalized human microvascular endothelial cell line. J. Invest. Dermatol. 99,683-690[Medline]
  5. Muruganandam, A., Herx, L. M., Monette, R., Durkin, J. P., Stanimirovic, D. B. (1997) Development of immortalized human cerebromicrovascular endothelial cell line as an in vitro model of the human blood–brain barrier. FASEB J 11,1187-1197[Abstract]
  6. Jiang, X. R., Jimenez, G., Chang, E., Frolkis, M., Kusler, B., Sage, M., Beeche, M., Bodnar, A. G., Wahl, G. M., Tlsty, T. D., Chiu, C. P. (1999) Telomerase expression in human somatic cells does not induce changes associated with a transformed phenotype. Nat. Genet. 21,111-114[Medline]
  7. Yang, J., Chang, E., Cherry, A. M., Bangs, C. D., Oei, Y., Bodnar, A., Bronstein, A., Chiu, C. P., Herron, G. S. (1999) Human endothelial cell life extension by telomerase expression. J. Biol. Chem. 274,26141-26148[Abstract/Free Full Text]
  8. Bond, J. A., Blaydes, J. P., Rowson, J., Haughton, M. F., Smith, J. R., Wynford-Thomas, D., Wyllie, F. S. (1995) Mutant p53 rescues human diploid cells from senescence without inhibiting the induction of SDI1/WAF1. Cancer Res 55,2404-2409[Abstract/Free Full Text]
  9. Dimri, G. P., Campisi, J. (1994) Molecular and cell biology of replicative senescence. Cold Spring Harbor Symp. Quant. Biol. 59,67-73[Medline]
  10. Dimri, G. P., Lee, X., Basile, G., Acosta, M., Scott, G., Roskelley, C., Medrano, E. E., Linskens, M., Rubelj, I., Pereira-Smith, O., Peacocke, M, Campisi, J. (1995) A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc. Natl. Acad. Sci. USA 92,9363-9367[Abstract/Free Full Text]
  11. Chang, B. D., Broude, E. V., Dokmanovic, M., Zhu, H., Ruth, A., Xuan, Y., Kandel, E. S., Lausch, E., Christov, K., Roninson, I. B. (1999) A senescence-like phenotype distinguishes tumor cells that undergo terminal proliferation arrest after exposure to anticancer agents. Cancer Res 59,3761-3767[Abstract/Free Full Text]
  12. Watanabe, Y., Lee, S. W., Detmar, M., Ajioka, I., Dvorak, H. F. (1997) Vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) delays and induces escape from senescence in human dermal microvascular endothelial cells. Oncogene 14,2025-2032[Medline]
  13. Kraling, B. M., Bischoff, J. (1998) A simplified method for growth of human microvascular endothelial cells results in decreased senescence and continued responsiveness to cytokines and growth factors. In Vitro Cell Dev. Biol. Anim. 34,308-3015[Medline]
  14. Maier, J. A., Voulalas, P., Roeder, D., Maciag, T. (1990) Extension of the life-span of human endothelial cells by an interleukin-1 alpha antisense oligomer. Science 249,1570-1574[Abstract/Free Full Text]
  15. Sholley, M. M., Cotran, R. S. (1976) Endothelial DNA synthesis in the microvasculature of rat skin during the hair growth cycle. Am. J. Anat. 147,243-254[Medline]
  16. Denekamp, J. (1990) Vascular attack as a therapeutic strategy for cancer. Cancer Metast. Rev. 9,267-282[Medline]
  17. Dvorak, H. F., Brown, L. F., Detmar, M., Dvorak, A. M. (1995) Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am. J. Pathol. 146,1029-1039[Abstract]
  18. Dvorak, H. F., Nagy, J. A., Feng, D., Brown, L. F., Dvorak, A. M. (1999) Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. Curr. Top. Microbiol. Immunol. 237,97-132[Medline]
  19. Senger, D. R., Van de Water, L., Brown, L. F., Nagy, J. A., Yeo, K. T., Yeo, T. K., Berse, B., Jackman, R. W., Dvorak, A. M., Dvorak, H. F. (1993) Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metast. Rev. 12,303-324[Medline]
  20. Rivard, A., Fabre, J. E., Silver, M., Chen, D., Murohara, T., Kearney, M., Magner, M., Asahara, T., Isner, J. M. (1999) Age-dependent impairment of angiogenesis. Circulation 99,111-120[Abstract/Free Full Text]
  21. Arthur, W. T., Vernon, R. B., Sage, E. H., Reed, M. J. (1998) Growth factors reverse the impaired sprouting of microvessels from aged mice. Microvasc. Res. 55,260-270[Medline]
  22. Pili, R., Guo, Y., Chang, J., Nakanishi, H., Martin, G. R., Passaniti, A. (1994) Altered angiogenesis underlying age-dependent changes in tumor growth. J. Natl. Cancer Inst. 86,1303-1314[Abstract/Free Full Text]
  23. Santelli, G., Califano, D., Chiappetta, G., Vento, M. T., Bartoli, P. C., Zullo, F., Trapasso, F., Viglietto, G., Fusco, A. (1999) Thymosin beta-10 gene overexpression is a general event in human carcinogenesis. Am. J. Pathol. 155,799-804[Abstract/Free Full Text]
  24. Carpintero, P., Franco del Amo, F., Anadon, R., Gomez-Marquez, J. (1996) Thymosin beta10 mRNA expression during early postimplantation mouse development. FEBS Lett 394,103-106[Medline]
  25. Yu, F. X., Lin, S. C., Morrison-Bogorad, M., Atkinson, M. A., Yin, H. L. (1993) Thymosin beta 10 and thymosin beta 4 are both actin monomer sequestering proteins. J. Biol. Chem. 268,502-509[Abstract/Free Full Text]
  26. Detmar, M., Imcke, E., Ruszczak, Z., Orfanos, C. E. (1990) Effects of recombinant tumor necrosis factor-alpha on cultured microvascular endothelial cells derived from human dermis. J. Invest. Dermatol. ,219S-222S
  27. Redgrave, T. G., Roberts, D. C., West, C. E. (1975) Separation of plasma lipoproteins by density-gradient ultracentrifugation. Anal. Biochem. 65,42-49[Medline]
  28. Vasile, E., Simionescu, M., Simionescu, N. (1983) Visualization of the binding, endocytosis, and transcytosis of low-density lipoprotein in the arterial endothelium in situ. J. Cell Biol. 96,1677-1689[Abstract/Free Full Text]
  29. Markwell, M. A., Haas, S. M., Bieber, L. L., Tolbert, N. E. (1978) A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples. Anal. Biochem. 87,206-210[Medline]
  30. Pitas, R. E. (1990) Expression of acetyl low density lipoprotein receptor by rabbit fibroblasts and smooth muscle cells. J. Biol. Chem. 265,12722-12727[Abstract/Free Full Text]
  31. Goldstein, J. L., Basu, S. K., Brown, M. S. (1983) Receptor-mediated endocytosis of low-density lipoprotein in cultured cells. Methods Enzymol 98,241-260[Medline]
  32. Bilheimer, D., Eisenberg, S., Levy, R. I. (1972) The metabolism of very low density lipoprotein proteins. I. Preliminary in vitro and in vivo observations. Biochim. Biophys. Acta 260,212-221[Medline]
  33. Ashkenas, J., Penman, M., Vasile, E., Acton, S., Freeman, M., Krieger, M. (1993) Structures and high and low affinity ligand binding properties of murine type I and type II macrophage scavenger receptors. J. Lipid Res. 34,983-1000[Abstract]
  34. Vasile, E., Qu, H., Dvorak, H. F., Dvorak, A. M. (1999) Caveolae and vesiculo-vacuolar organelles in bovine capillary endothelial cells cultured with VPF/VEGF on floating Matrigel-collagen gels. J. Histochem. Cytochem. 47,159-167[Abstract/Free Full Text]
  35. Brown, L. F., Yeo, K. T., Berse, B., Yeo, T. K., Senger, D. R., Dvorak, H. F., van de Water, L. (1992) Expression of vascular permeability factor (vascular endothelial growth factor) by epidermal keratinocytes during wound healing. J. Exp. Med. 176,1375-1379[Abstract/Free Full Text]
  36. Steinberg, D. (1997) Low density lipoprotein oxidation and its pathobiological significance. J. Biol. Chem. 272,20963-20966[Free Full Text]
  37. Krieger, M., Herz, J. (1994) Structures and functions of multiligand lipoprotein receptors: macrophage scavenger receptors and LDL receptor-related protein (LRP). Annu. Rev. Biochem. 63,601-637[Medline]
  38. Califano, D., Monaco, C., Santelli, G., Giuliano, A., Veronese, M. L., Berlingieri, M. T., de Franciscis, V., Berger, N., Trapasso, F., Santoro, M., Viglietto, G., Fusco, A. (1998) Thymosin beta-10 gene overexpression correlated with the highly malignant neoplastic phenotype of transformed thyroid cells in vivo and in vitro. Cancer Res 58,823-828[Abstract/Free Full Text]
  39. Levine, E. M., Mueller, S. N. (1979) Cultured vascular endothelial cells as a model system for the study of cellular senescence. Int. Rev. Cytol. Suppl. 1979,67-76
  40. de Boer, O. J., van der Wal, A. C., Teeling, P., Becker, A. E. (1999) Leucocyte recruitment in rupture prone regions of lipid-rich plaques: a prominent role for neovascularization?. Cardiovasc. Res. 41,443-449[Abstract/Free Full Text]
  41. Vasile, E., Antohe, F., Simionescu, M., Simionescu, N. (1989) Transport pathways of beta-VLDL by aortic endothelium of normal and hypercholesterolemic rabbits. Atherosclerosis 75,195-210[Medline]
  42. Vasile, E., Antohe, F. (1991) An ultrastructural study of beta-very low density lipoprotein uptake and transport by valvular endothelium of hyperlipidemic rabbits. J. Submicrosc. Cytol. Pathol. 23,279-287[Medline]
  43. Burrig, K. F. (1991) The endothelium of advanced arteriosclerotic plaques in humans. Arterioscler. Thromb. 11,1678-1689[Abstract/Free Full Text]
  44. Negre-Salvayre, A., Fitoussi, G., Reaud, V., Pieraggi, M. T., Thiers, J. C., Salvayre, R. (1992) A delayed and sustained rise of cytosolic calcium is elicited by oxidized LDL in cultured bovine aortic endothelial cells. FEBS Lett 299,60-65[Medline]
  45. Rajavashisth, T. B., Andalibi, A., Territo, M. C., Berliner, J. A., Navab, M., Fogelman, A. M., Lusis, A. J. (1990) Induction of endothelial cell expression of granulocyte and macrophage colony-stimulating factors by modified low-density lipoproteins. Nature (London) 344,254-257[Medline]
  46. Maier, J. A., Barenghi, L., Bradamante, S., Pagani, F. (1996) Induction of human endothelial cell growth by mildly oxidized low density lipoprotein. Atherosclerosis 123,115-121[Medline]
  47. Zhu, W., Roma, P., Pirillo, A., Pellegatta, F., Catapano, A. L. (1996) Human endothelial cells exposed to oxidized LDL express hsp70 only when proliferating. Arterioscler. Thromb. Vasc. Biol. 16,1104-1111[Abstract/Free Full Text]
  48. Shelton, D. N., Chang, E., Whittier, P. S., Choi, D., Funk, W. D. (1999) Microarray analysis of replicative senescence. Curr. Biol. 9,939-945[Medline]
  49. Hall, A. K., Hempstead, J., Morgan, J. I. (1990) Thymosin beta 10 levels in developing human brain and its regulation by retinoic acid in the HTB-10 neuroblastoma. Brain Res. Mol Brain Res. 8,1291-1235
  50. Roth, L. W., Bormann, P., Wiederkehr, C., Reinhard, E. (1999) Beta-thymosin, a modulator of the actin cytoskeleton is increased in regenerating retinal ganglion cells. Eur. J. Neurosci. 11,3488-3498[Medline]
  51. Yu, F. X., Lin, S. C., Morrison-Bogorad, M., Yin, H. L. (1994) Effects of thymosin beta 4 and thymosin beta 10 on actin structures in living cells. Cell Motil. Cytoskel. 27,13-25[Medline]
  52. Sun, H. Q., Kwiatkowska, K., Yin, H. L. (1996) beta-Thymosins are not simple actin monomer buffering proteins. Insights from overexpression studies. J. Biol. Chem. 271,9223-9230[Abstract/Free Full Text]
  53. Hall, A. K. (1995) Thymosin beta-10 accelerates apoptosis. Cell. Mol. Biol. Res. 41,167-180[Medline]



This article has been cited by other articles:


Home page
J. Cell Sci.Home page
A. S. Multani and S. Chang
WRN at telomeres: implications for aging and cancer
J. Cell Sci., March 1, 2007; 120(5): 713 - 721.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
T. Minamino and I. Komuro
Vascular Cell Senescence: Contribution to Atherosclerosis
Circ. Res., January 5, 2007; 100(1): 15 - 26.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J.-P. Coppe, K. Kauser, J. Campisi, and C. M. Beausejour
Secretion of Vascular Endothelial Growth Factor by Primary Human Fibroblasts at Senescence
J. Biol. Chem., October 6, 2006; 281(40): 29568 - 29574.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
I. Gorenne, M. Kavurma, S. Scott, and M. Bennett
Vascular smooth muscle cell senescence in atherosclerosis
Cardiovasc Res, October 1, 2006; 72(1): 9 - 17.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
T. Kunieda, T. Minamino, J.-i. Nishi, K. Tateno, T. Oyama, T. Katsuno, H. Miyauchi, M. Orimo, S. Okada, M. Takamura, et al.
Angiotensin II Induces Premature Senescence of Vascular Smooth Muscle Cells and Accelerates the Development of Atherosclerosis via a p21-Dependent Pathway
Circulation, August 29, 2006; 114(9): 953 - 960.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
C. Matthews, I. Gorenne, S. Scott, N. Figg, P. Kirkpatrick, A. Ritchie, M. Goddard, and M. Bennett
Vascular Smooth Muscle Cells Undergo Telomere-Based Senescence in Human Atherosclerosis: Effects of Telomerase and Oxidative Stress
Circ. Res., July 21, 2006; 99(2): 156 - 164.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Sci.Home page
S. Parrinello, J.-P. Coppe, A. Krtolica, and J. Campisi
Stromal-epithelial interactions in aging and cancer: senescent fibroblasts alter epithelial cell differentiation
J. Cell Sci., February 1, 2005; 118(3): 485 - 496.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
J. O. d. Buijs, M. Musters, T. Verrips, J. A. Post, B. Braam, and N. van Riel
Mathematical modeling of vascular endothelial layer maintenance: the role of endothelial cell division, progenitor cell homing, and telomere shortening
Am J Physiol Heart Circ Physiol, December 1, 2004; 287(6): H2651 - H2658.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
A. Seluanov, D. Mittelman, O. M. Pereira-Smith, J. H. Wilson, and V. Gorbunova
DNA end joining becomes less efficient and more error-prone during cellular senescence
PNAS, May 18, 2004; 101(20): 7624 - 7629.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Sci.Home page
D. J. Kurz, S. Decary, Y. Hong, E. Trivier, A. Akhmedov, and J. D. Erusalimsky
Chronic oxidative stress compromises telomere integrity and accelerates the onset of senescence in human endothelial cells
J. Cell Sci., May 1, 2004; 117(11): 2417 - 2426.
[Abstract] [Full Text] [PDF]


Home page
J. Appl. Physiol.Home page
B. T. Weinert and P. S. Timiras
Invited Review: Theories of aging
J Appl Physiol, October 1, 2003; 95(4): 1706 - 1716.
[Abstract] [Full Text] [PDF]


Home page
J. Gerontol. A Biol. Sci. Med. Sci.Home page
J. R. Smith
Author's Response to Commentary: Cell Senescence: An Evaluation of Replicative Senescence in Culture as a Model for Aging In Situ
J. Gerontol. A Biol. Sci. Med. Sci., September 1, 2003; 58(9): B779 - 781.
[Full Text] [PDF]


Home page